Cogent Biosciences (COGT) Amortization of Deferred Charges (2021 - 2026)

Cogent Biosciences (COGT) has 6 years of Amortization of Deferred Charges data on file, last reported at $278000.0 in Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges fell 44.18% year-over-year to $278000.0 in Q1 2026; TTM through Mar 2026 was $1.8 million, a 6.88% decrease from a year earlier, with the FY2025 full-year figure at $2.0 million, up 6.21% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $278000.0, down from $1.7 million in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for COGT reached as high as $3.5 million in Q3 2022 and fell as low as -$435000.0 in Q2 2025.
• Historically, Amortization of Deferred Charges has averaged $620705.9 across 5 years, with a median of $477000.0 in 2024.
• Across the five-year window, Amortization of Deferred Charges surged 641.42% in 2022 and sank 191.77% in 2025, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $517000.0 in 2022, then slumped by 62.09% to $196000.0 in 2023, then jumped by 146.43% to $483000.0 in 2024, then soared by 242.86% to $1.7 million in 2025, then plunged by 83.21% to $278000.0 in 2026.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $278000.0 in Q1 2026, $1.7 million in Q4 2025, and $300000.0 in Q3 2025.